Clinical Assessment of Essential Remote Monitoring Functions in Pacemakers

Inclusion Criteria:

1. Patient implanted according to the most recent guidelines from the ESC, for 20 daysor less (de novo implantation, device upgrade to dual chamber or device replacement)

2. Patient implanted with an ALIZEA, BOREA or CELEA dual chamber pacemaker fromMicroPort CRM

3. Patient implanted with any active or passive CE marked bipolar RA lead, and anyactive or passive CE marked bipolar RV lead

4. Patient's pacemaker with the remote monitoring functions (i.e. the RAAT, the RVATand the remote alerts) accepted by the patient and planned to be activated

5. Patient reviewed, signed and dated the ICF

Exclusion Criteria:

1. Patient with an elevated RV pacing threshold (strictly above 2.0 V for a pulse widthof 0.5 ms or below)

2. Patient with permanent AF

3. Patient already enrolled in another clinical investigation that could confound theresults of this clinical investigation (e.g., clinical investigations involvingintra-cardiac device)

4. Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a singledose of 310 μg of dexamethasone sodium phosphate, patient implanted with a tricuspidreplacement heart valve or with a significant tricuspid valve disease that may leadto future replacement heart valve surgery)

5. Minor age patient (i.e. under 18 years of age)

6. Incapacitated patient, under guardianship, kept in detention, refusing to cooperateor not able to understand the purpose of this clinical investigation

7. Patient unavailable for the follow-up visits scheduled

8. Non-menopausal women